$SCLX
Scilex Holding Co Stock $sclx

$sclx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024029473 Filed on March 12, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$10.88M	$13.46M	$46.74M
YoY Change	2.85%	12.95%	22.9%
Cost Of Revenue	$3.840M	$4.521M	$15.68M
YoY Change	6.93%	0.18%	45.23%
Gross Profit	$7.044M	$8.941M	$31.06M
YoY Change	0.76%	20.73%	14.04%
Gross Profit Margin	64.72%	66.42%	66.45%
Selling, General & Admin	$29.28M	$23.52M	$119.6M
YoY Change	2.01%	-0.02%	84.36%
% of Gross Profit	415.64%	263.06%	385.17%
Research & Development	$3.108M	$2.734M	$12.75M
YoY Change	13.6%	5.28%	40.78%
% of Gross Profit	44.12%	30.58%	41.03%
Depreciation & Amortization	$1.031M	$1.034M	$4.146M
YoY Change	-0.58%	-0.1%	4.67%
% of Gross Profit	14.64%	11.56%	13.35%
Operating Expenses	$32.39M	$27.28M	$132.4M
YoY Change	3.02%	0.49%	79.02%
Operating Profit	-$19.50M	-$18.34M	-$105.4M
YoY Change	-23.53%	-7.1%	108.3%
Interest Expense	$531.0K	-$3.053M	$1.068M
YoY Change	-110.07%	-260.94%	-88.88%
% of Operating Profit
Other Income/Expense, Net		$0.00	-$8.887M
YoY Change			-132.58%
Pretax Income	-$24.38M	-$21.39M	-$114.3M
YoY Change	-20.71%	19.88%	389.38%
Income Tax	$0.00	$8.000K	$13.00K
% Of Pretax Income
Net Earnings	-$24.38M	-$21.40M	-$114.3M
YoY Change	-20.73%	19.66%	389.35%
Net Earnings / Revenue	-223.97%	-158.97%	-244.59%
Basic Earnings Per Share	-$0.24		-$1.28
Diluted Earnings Per Share	-$0.24	-$0.22	-$1.28
COMMON SHARES
Basic Shares Outstanding	166.2M	155.9M	130.3M
Diluted Shares Outstanding	102.4K		130.3M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$3.921M	$3.921M
YoY Change		79.53%	79.53%
Cash & Equivalents	$1.800M	$3.900M	$3.921M
Short-Term Investments
Other Short-Term Assets		$4.049M	$4.049M
YoY Change		-15.82%	-15.82%
Inventory	$3.486M	$4.214M	$4.214M
Prepaid Expenses
Receivables	$29.72M	$34.60M	$34.60M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$37.75M	$46.78M	$46.78M
YoY Change	21.35%	58.0%	58.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$718.0K	$722.0K	$3.665M
YoY Change	-5.77%	-6.48%	92.59%
Goodwill	$13.50M	$13.50M
YoY Change	0.0%	0.0%
Intangibles	$35.46M	$36.49M
YoY Change	-10.38%	-10.12%
Long-Term Investments
YoY Change
Other Assets		$897.0K	$897.0K
YoY Change		-4.98%	-4.98%
Total Long-Term Assets	$53.50M	$54.53M	$54.53M
YoY Change	-2.64%	-4.2%	-4.2%
TOTAL ASSETS
Total Short-Term Assets	$37.75M	$46.78M	$46.78M
Total Long-Term Assets	$53.50M	$54.53M	$54.53M
Total Assets	$91.24M	$101.3M	$101.3M
YoY Change	6.03%	17.08%	17.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$42.22M	$40.95M	$40.95M
YoY Change	330.06%	384.66%	384.66%
Accrued Expenses		$100.5M	$100.5M
YoY Change		178.19%	178.19%
Deferred Revenue
YoY Change
Short-Term Debt		$108.4M	$108.4M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$252.7M	$250.4M	$250.4M
YoY Change	291.21%	458.36%	458.36%
LONG-TERM LIABILITIES
Long-Term Debt		$17.04M	$17.04M
YoY Change
Other Long-Term Liabilities	$182.0K	$179.0K	$6.829M
YoY Change	8.33%	9.82%	25.39%
Total Long-Term Liabilities	$182.0K	$179.0K	$23.87M
YoY Change	8.33%	9.82%	338.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$252.7M	$250.4M	$250.4M
Total Long-Term Liabilities	$182.0K	$179.0K	$23.87M
Total Liabilities	$281.0M	$274.2M	$274.2M
YoY Change	274.83%	445.35%	445.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$514.6M	-$490.2M
YoY Change	26.53%	30.41%
Common Stock	$17.00K	$16.00K
YoY Change	13.33%	14.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$90.52M	$90.52M
YoY Change
Treasury Stock Shares
Shareholders Equity	-$189.8M	-$172.9M	-$172.9M
YoY Change
Total Liabilities & Shareholders Equity	$91.24M	$101.3M	$101.3M
YoY Change	6.03%	17.08%	17.08%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$24.38M	-$21.40M	-$114.3M
YoY Change	-20.73%	19.66%	389.35%
Depreciation, Depletion And Amortization	$1.031M	$1.034M	$4.146M
YoY Change	-0.58%	-0.1%	4.67%
Cash From Operating Activities	$9.391M	-$5.390M	-$20.71M
YoY Change	-221.27%	643.45%	-2.59%
INVESTING ACTIVITIES
Capital Expenditures		$167.0K	$30.00K
YoY Change			328.57%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$150.0K	-$167.0K	-$330.0K
YoY Change			-84.03%
FINANCING ACTIVITIES
Cash Dividend Paid			$8.650M
YoY Change
Common Stock Issuance & Retirement, Net			$35.46M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-11.20M	8.306M	23.58M
YoY Change	-205.33%	1849.77%	11.39%
NET CHANGE
Cash From Operating Activities	9.391M	-5.390M	-20.71M
Cash From Investing Activities	-150.0K	-167.0K	-330.0K
Cash From Financing Activities	-11.20M	8.306M	23.58M
Net Change In Cash	-1.955M	2.749M	2.545M
YoY Change	-167.76%	-1019.4%	-218.15%
FREE CASH FLOW
Cash From Operating Activities	$9.391M	-$5.390M	-$20.71M
Capital Expenditures		$167.0K	$30.00K
Free Cash Flow		-$5.557M	-$20.74M
YoY Change		666.48%	-2.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001820190
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
CY2022Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
CY2023Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#DerivativeLiabilitiesNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39852
CY2023	dei	Entity Registrant Name EntityRegistrantName	Scilex Holding Company
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	92-1062542
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	960 San Antonio Road
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94303
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	516-4310
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	SCLX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	479560000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	166189835
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3921000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2184000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	34597000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21236000
CY2023Q4	us-gaap	Inventory Net InventoryNet	4214000
CY2022Q4	us-gaap	Inventory Net InventoryNet	1378000
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4049000
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	4810000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	46781000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	29608000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	722000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2943000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1131000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	36485000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	40591000
CY2023Q4	us-gaap	Goodwill Goodwill	13481000
CY2022Q4	us-gaap	Goodwill Goodwill	13481000
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	897000
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	944000
CY2023Q4	us-gaap	Assets Assets	101309000
CY2022Q4	us-gaap	Assets Assets	86527000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	40954000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8450000
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2681000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1354000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	89658000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30893000
CY2023Q4	sclx	Accrued Expenses AccruedExpenses	7408000
CY2022Q4	sclx	Accrued Expenses AccruedExpenses	3136000
CY2023Q4	sclx	Current Portion Of Deferred Consideration CurrentPortionOfDeferredConsideration	491000
CY2022Q4	sclx	Current Portion Of Deferred Consideration CurrentPortionOfDeferredConsideration	264000
CY2023Q4	us-gaap	Debt Current DebtCurrent	108429000
CY2022Q4	us-gaap	Debt Current DebtCurrent	0
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	759000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	745000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	250380000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	44842000
CY2023Q4	sclx	Long Term Portion Of Deferred Consideration LongTermPortionOfDeferredConsideration	2895000
CY2022Q4	sclx	Long Term Portion Of Deferred Consideration LongTermPortionOfDeferredConsideration	3387000
CY2023Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	17038000
CY2022Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	0
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1518000
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1231000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2237000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	665000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	179000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163000
CY2023Q4	us-gaap	Liabilities Liabilities	274247000
CY2022Q4	us-gaap	Liabilities Liabilities	50288000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	45000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	45000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29057097
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29057097
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	29057097
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	29057097
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	740000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	740000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160084250
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100015665
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	141348856
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	141348856
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	14000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	407813000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412136000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-490245000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375914000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	60068585
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	90522000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-172938000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	36239000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101309000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86527000
CY2023	us-gaap	Revenues Revenues	46743000
CY2022	us-gaap	Revenues Revenues	38034000
CY2021	us-gaap	Revenues Revenues	31317000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	15681000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	10797000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3634000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12746000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9054000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9201000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	119641000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64895000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50582000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4106000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3922000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3738000
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	152174000
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	88668000
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	67155000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-105431000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-50634000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-35838000
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-512000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8310000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2023	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	7189000
CY2022	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
CY2021	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28634000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12463000
CY2023	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2022	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2021	sclx	Notes Principal Increase NotesPrincipalIncrease	-28000000
CY2023	us-gaap	Interest Expense InterestExpense	1068000
CY2022	us-gaap	Interest Expense InterestExpense	9604000
CY2021	us-gaap	Interest Expense InterestExpense	11764000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-118000
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-66000
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-54000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8887000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27274000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-52581000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-114318000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23360000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-88419000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-114331000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23364000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88424000
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130298000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	130298000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134226000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134226000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132858000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132858000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-141683000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5822000
CY2021	sclx	Adjustment To Shares Issued In Semnur Acquisition Value AdjustmentToSharesIssuedInSemnurAcquisitionValue	409000
CY2021	us-gaap	Profit Loss ProfitLoss	-88424000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-223876000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	96000
CY2022	sclx	Adjustment To Additional Paid In Capital License Transfer Net Of Discount Value AdjustmentToAdditionalPaidInCapitalLicenseTransferNetOfDiscountValue	-4127000
CY2022	sclx	Adjustmenttoadditionalpaidincapitaldiscountamortization Adjustmenttoadditionalpaidincapitaldiscountamortization	-35000
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	289733000
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	8706000
CY2022	sclx	Shares Issued To Yorkville Pursuant To Yorkville Purchase Agreement SharesIssuedToYorkvillePursuantToYorkvillePurchaseAgreement	1238000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5280000
CY2022	us-gaap	Profit Loss ProfitLoss	-23364000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	36239000
CY2023	sclx	Value Issued Under Standby Equity Purchase Agreements ValueIssuedUnderStandbyEquityPurchaseAgreements	34257000
CY2023	sclx	Disbursement Of Funds To Sorrento Amount DisbursementOfFundsToSorrentoAmount	-20000000
CY2023	sclx	Stock Issued During Period Repurchase Of Treasury Stock Preferred Stock And Warrants Value StockIssuedDuringPeriodRepurchaseOfTreasuryStockPreferredStockAndWarrantsValue	-143721000
CY2023	sclx	Issuance Of Penny Warrants IssuanceOfPennyWarrants	10401000
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	750000
CY2023	sclx	Conversion Of Convertible Debentures Into Common Stock Value ConversionOfConvertibleDebenturesIntoCommonStockValue	7735000
CY2023	sclx	Retainer Shares Issued Value RetainerSharesIssuedValue	1000
CY2023	sclx	Issuance Of Common Stock Upon Warrants Exercise Value IssuanceOfCommonStockUponWarrantsExerciseValue	521000
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	614000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14596000
CY2023	us-gaap	Profit Loss ProfitLoss	-114331000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-172938000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-114331000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23364000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88424000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4146000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3961000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3779000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	65000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3142000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7909000
CY2023	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2022	sclx	Notes Principal Increase NotesPrincipalIncrease	0
CY2021	sclx	Notes Principal Increase NotesPrincipalIncrease	-28000000
CY2023	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	0
CY2022	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	21190000
CY2021	sclx	Payment On The Scilex Pharma Notes Attributed To Accreted Interest Related To The Debt Discount PaymentOnTheScilexPharmaNotesAttributedToAccretedInterestRelatedToTheDebtDiscount	12487000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	28634000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-12463000
CY2023	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	507000
CY2022	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	492000
CY2021	sclx	Non Cash Operating Lease Cost NonCashOperatingLeaseCost	372000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	14596000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	5280000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5822000
CY2023	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	750000
CY2022	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	0
CY2021	us-gaap	Proceeds From Insurance Settlement Operating Activities ProceedsFromInsuranceSettlementOperatingActivities	0
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-512000
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	8310000
CY2021	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-300000
CY2023	sclx	Forfeitures Of Private Warrants ForfeituresOfPrivateWarrants	0
CY2022	sclx	Forfeitures Of Private Warrants ForfeituresOfPrivateWarrants	1697000
CY2021	sclx	Forfeitures Of Private Warrants ForfeituresOfPrivateWarrants	0
CY2023	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	7189000
CY2022	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
CY2021	sclx	Change In Fair Value Of Debt And Liability Instruments ChangeInFairValueOfDebtAndLiabilityInstruments	0
CY2023	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	57000
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13361000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6968000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1142000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2838000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1184000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1417000
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	441000
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2629000
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1479000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-855000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-350000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	19880000
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2806000
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3836000
CY2023	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	1327000
CY2022	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-2379000
CY2021	sclx	Increase Decrease In Accrued Payroll IncreaseDecreaseInAccruedPayroll	-21000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2310000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-123000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	664000
CY2023	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	58765000
CY2022	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	23531000
CY2021	sclx	Increase Decrease In Accrued Rebates And Fees IncreaseDecreaseInAccruedRebatesAndFees	-255000
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-711000
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-392000
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-80000
CY2023	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	0
CY2022	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	30125000
CY2021	us-gaap	Increase Decrease In Notes Payable Related Parties Current IncreaseDecreaseInNotesPayableRelatedPartiesCurrent	18210000
CY2023	sclx	Other Long Term Liabilities OtherLongTermLiabilities	16000
CY2022	sclx	Other Long Term Liabilities OtherLongTermLiabilities	163000
CY2021	sclx	Other Long Term Liabilities OtherLongTermLiabilities	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20707000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21258000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28664000
CY2023	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	300000
CY2022	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	2060000
CY2021	sclx	Acquisition Consideration Paid In Cash For Romeg Intangible Asset Acquisition AcquisitionConsiderationPaidInCashForRomegIntangibleAssetAcquisition	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-330000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2067000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35458000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	24000000
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	15625000
CY2022	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2021	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2023	sclx	Proceeds From Issuance Of Revolving Facility ProceedsFromIssuanceOfRevolvingFacility	86354000
CY2022	sclx	Proceeds From Issuance Of Revolving Facility ProceedsFromIssuanceOfRevolvingFacility	0
CY2021	sclx	Proceeds From Issuance Of Revolving Facility ProceedsFromIssuanceOfRevolvingFacility	0
CY2023	sclx	Repayment Of Revolving Facility RepaymentOfRevolvingFacility	69001000
CY2022	sclx	Repayment Of Revolving Facility RepaymentOfRevolvingFacility	0
CY2021	sclx	Repayment Of Revolving Facility RepaymentOfRevolvingFacility	0
CY2023	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	5000000
CY2022	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	0
CY2021	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	0
CY2023	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	1372000
CY2022	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	2949000
CY2021	sclx	Transaction Costs Paid Related To The Recapitalization Transaction TransactionCostsPaidRelatedToTheRecapitalizationTransaction	0
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	380000
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2023	sclx	Disbursement Of Funds DisbursementOfFunds	-20000000
CY2022	sclx	Disbursement Of Funds DisbursementOfFunds	0
CY2021	sclx	Disbursement Of Funds DisbursementOfFunds	0
CY2023	us-gaap	Accelerated Share Repurchases Adjustment To Recorded Amount AcceleratedShareRepurchasesAdjustmentToRecordedAmount	-10000000
CY2022	us-gaap	Accelerated Share Repurchases Adjustment To Recorded Amount AcceleratedShareRepurchasesAdjustmentToRecordedAmount	0
CY2021	us-gaap	Accelerated Share Repurchases Adjustment To Recorded Amount AcceleratedShareRepurchasesAdjustmentToRecordedAmount	0
CY2023	sclx	Transaction Costs Paid In Connection With Share Repurchase TransactionCostsPaidInConnectionWithShareRepurchase	1987000
CY2022	sclx	Transaction Costs Paid In Connection With Share Repurchase TransactionCostsPaidInConnectionWithShareRepurchase	0
CY2021	sclx	Transaction Costs Paid In Connection With Share Repurchase TransactionCostsPaidInConnectionWithShareRepurchase	0
CY2023	sclx	Proceeds From The Business Combination ProceedsFromTheBusinessCombination	0
CY2022	sclx	Proceeds From The Business Combination ProceedsFromTheBusinessCombination	3375000
CY2021	sclx	Proceeds From The Business Combination ProceedsFromTheBusinessCombination	0
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1135000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	96000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	51900000
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	47850000
CY2023	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	0
CY2022	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	62500000
CY2021	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	14700000
CY2023	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	0
CY2022	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	9857000
CY2021	us-gaap	Proceeds From Other Short Term Debt ProceedsFromOtherShortTermDebt	47832000
CY2023	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	0
CY2022	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	-84808000
CY2021	sclx	Repayment Of Principal On The Scilex Pharma Notes RepaymentOfPrincipalOnTheScilexPharmaNotes	-33387000
CY2023	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	0
CY2022	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	-18800000
CY2021	sclx	Proceeds From Repayment Of Loans To Purchase ProceedsFromRepaymentOfLoansToPurchase	-48832000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23582000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21171000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28163000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2545000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2154000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-501000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2184000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4338000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4839000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4729000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2184000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4338000
CY2023	us-gaap	Interest Income Operating Paid In Cash InterestIncomeOperatingPaidInCash	1426000
CY2022	us-gaap	Interest Income Operating Paid In Cash InterestIncomeOperatingPaidInCash	0
CY2021	us-gaap	Interest Income Operating Paid In Cash InterestIncomeOperatingPaidInCash	0
CY2023	us-gaap	Stock Issued1 StockIssued1	1869000
CY2022	us-gaap	Stock Issued1 StockIssued1	0
CY2021	us-gaap	Stock Issued1 StockIssued1	0
CY2023	sclx	Conversion Of Convertible Debentures Into Common Stock ConversionOfConvertibleDebenturesIntoCommonStock	7735000
CY2022	sclx	Conversion Of Convertible Debentures Into Common Stock ConversionOfConvertibleDebenturesIntoCommonStock	0
CY2021	sclx	Conversion Of Convertible Debentures Into Common Stock ConversionOfConvertibleDebenturesIntoCommonStock	0
CY2023	sclx	Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities With Lease Modification RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification	2523000
CY2022	sclx	Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities With Lease Modification RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification	0
CY2021	sclx	Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities With Lease Modification RightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilitiesWithLeaseModification	0
CY2023	sclx	Oramed Note Issuance At Fair Value OramedNoteIssuanceAtFairValue	106252000
CY2022	sclx	Oramed Note Issuance At Fair Value OramedNoteIssuanceAtFairValue	0
CY2021	sclx	Oramed Note Issuance At Fair Value OramedNoteIssuanceAtFairValue	0
CY2023	sclx	Other Non Cash Consideration In Connection With Share Repurchase OtherNonCashConsiderationInConnectionWithShareRepurchase	26154000
CY2022	sclx	Other Non Cash Consideration In Connection With Share Repurchase OtherNonCashConsiderationInConnectionWithShareRepurchase	0
CY2021	sclx	Other Non Cash Consideration In Connection With Share Repurchase OtherNonCashConsiderationInConnectionWithShareRepurchase	0
CY2023	sclx	Excise Tax In Connection With Share Repurchase Included In Accrued Expenses ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses	1310000
CY2022	sclx	Excise Tax In Connection With Share Repurchase Included In Accrued Expenses ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses	0
CY2021	sclx	Excise Tax In Connection With Share Repurchase Included In Accrued Expenses ExciseTaxInConnectionWithShareRepurchaseIncludedInAccruedExpenses	0
CY2023	sclx	Related Party Debt Converted To Equity Pursuant To Debt Exchange Agreement RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement	0
CY2022	sclx	Related Party Debt Converted To Equity Pursuant To Debt Exchange Agreement RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement	289733000
CY2021	sclx	Related Party Debt Converted To Equity Pursuant To Debt Exchange Agreement RelatedPartyDebtConvertedToEquityPursuantToDebtExchangeAgreement	0
CY2023	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	0
CY2022	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	3650000
CY2021	sclx	Deferred Consideration For Romeg Intangible Asset Acquisition DeferredConsiderationForRomegIntangibleAssetAcquisition	0
CY2023	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	0
CY2022	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	4162000
CY2021	sclx	Promissory Note Issued To Sorrento In Exchange For The Sp104 License Net Of Discount PromissoryNoteIssuedToSorrentoInExchangeForTheSp104LicenseNetOfDiscount	0
CY2023	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	0
CY2022	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	30400000
CY2021	sclx	Fair Value Adjustment To Derivative Liability In Troubled Debt Restructuring FairValueAdjustmentToDerivativeLiabilityInTroubledDebtRestructuring	0
CY2023	sclx	Scilex Pharma Notes Principal Increase ScilexPharmaNotesPrincipalIncrease	0
CY2022	sclx	Scilex Pharma Notes Principal Increase ScilexPharmaNotesPrincipalIncrease	0
CY2021	sclx	Scilex Pharma Notes Principal Increase ScilexPharmaNotesPrincipalIncrease	-28000000
CY2023	sclx	Transaction Costs Obligation Assumed By Sorrento TransactionCostsObligationAssumedBySorrento	0
CY2022	sclx	Transaction Costs Obligation Assumed By Sorrento TransactionCostsObligationAssumedBySorrento	5148000
CY2021	sclx	Transaction Costs Obligation Assumed By Sorrento TransactionCostsObligationAssumedBySorrento	0
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3200000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of these consolidated financial statements and the reported amounts of expenses during the reporting period. Management believes that these estimates are reasonable; however, actual results may differ from these estimates.</span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Prior to April 2022, sales to the Company’s sole distributor represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of net revenue. In</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> April 2022, the Company announced the expansion of its direct distribution network to national and regional wholesalers and pharmacies. The Company had three and four customers during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, respectively, each of which individually generated </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% or more of the Company’s total revenue. These customers accounted for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">83</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of the Company’s revenue for the years ended December 31, 2023 and 2022, respectively, individually ranging from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2023 and 2022, these customers represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the Company’s outstanding accounts receivable, respectively, individually ranging between </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for both periods. Additionally, during the years ended December 31, 2023 and 2022, the Company purchased ZTlido inventory from its sole supplier, Itochu Chemical Frontier Corporation (“Itochu”). This exposes the Company to concentration of customer and supplier risk. The Company monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during the years ended December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3921000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2184000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	808000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4729000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2184000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-105400000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	250000
CY2023Q2	sclx	Principal Laon Amount PrincipalLaonAmount	30000000
CY2023	sclx	Outstanding Balance Of Revolving Facility OutstandingBalanceOfRevolvingFacility	17000000
CY2023	sclx	Treasury Stock Policy Textblock TreasuryStockPolicyTextblock	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the cost method to account for repurchases of its stock. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the computation of net (loss) income per share, treasury shares are not included as part of the outstanding shares.</span></p>
CY2023Q4	sclx	Working Capital WorkingCapital	203600000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3900000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	20700000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-490200000
CY2023	sclx	Accrued Royalty Payables AccruedRoyaltyPayables	5000
CY2023	sclx	Payment To Acquire License PaymentToAcquireLicense	0
CY2023Q4	us-gaap	Senior Notes SeniorNotes	104089000
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	4340000
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1518000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	179000
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	110126000
CY2022Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	1231000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	163000
CY2022Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	1394000
CY2023	sclx	Secured Note Discount Rate SecuredNoteDiscountRate	0.1305
CY2023Q2	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	25000000
CY2023	sclx	Change In Fair Value Of Convertible Debentures Include Interest Expense ChangeInFairValueOfConvertibleDebenturesIncludeInterestExpense	4400000
CY2023Q4	sclx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1	0.0531
CY2023Q4	sclx	Corporate Bond Yield CorporateBondYield	0.156
CY2023Q4	sclx	Coupon Interest Rate CouponInterestRate	0.07
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.70
CY2023Q4	sclx	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate1 ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1	0
CY2023Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	30400000
CY2022Q2	sclx	Risk Adjusted Net Sales Forecast RiskAdjustedNetSalesForecast	0.061
CY2022Q2	us-gaap	Debt Securities Available For Sale Weighted Average Yield DebtSecuritiesAvailableForSaleWeightedAverageYield	0.215
CY2023	sclx	Derivative Warrant Liability Private Warrants DerivativeWarrantLiabilityPrivateWarrants	1500000
CY2023	sclx	Equity Value EquityValue	2.04
CY2022	sclx	Equity Value EquityValue	3.99
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	11.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y10M9D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M9D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.76
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.35
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.039
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0394
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	sclx	Call Option Value CallOptionValue	0.42
CY2022	sclx	Call Option Value CallOptionValue	0.3
CY2023	us-gaap	Asset Acquisition Consideration Transferred Contingent Consideration AssetAcquisitionConsiderationTransferredContingentConsideration	3000000
CY2023Q4	us-gaap	Product Liability Contingency Accrual Discount Rate ProductLiabilityContingencyAccrualDiscountRate	0.102
CY2023	sclx	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	200000
CY2022	sclx	Fair Value Of Contingent Consideration FairValueOfContingentConsideration	200000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	780000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	939000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	167000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	722000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	772000
CY2023	us-gaap	Depreciation Depreciation	40000
CY2022	us-gaap	Depreciation Depreciation	40000
CY2021	us-gaap	Depreciation Depreciation	39000
CY2023	sclx	Accrued Expenses Textblock AccruedExpensesTextblock	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accrued expenses consists of the following (in thousands):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:75.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:54.28%;"></td> <td style="width:1.34%;"></td> <td style="width:1%;"></td> <td style="width:18.94%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:20.44%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,</span></p></td> <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:middle;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2022</span></p></td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued professional service fees</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,029</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,024</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued sales and marketing costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,601</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">574</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued research and development costs</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,546</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">459</span></p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued tax payable</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,452</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">—</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued others</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">780</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">79</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued expenses</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">7,408</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,136</span></p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2029000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2024000
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1601000
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	574000
CY2023Q4	sclx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	1546000
CY2022Q4	sclx	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	459000
CY2023Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	1452000
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	0
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	780000
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	79000
CY2023Q4	sclx	Accrued Expenses AccruedExpenses	7408000
CY2022Q4	sclx	Accrued Expenses AccruedExpenses	3136000
CY2023Q4	us-gaap	Goodwill Goodwill	13500000
CY2022Q4	us-gaap	Goodwill Goodwill	13500000
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	60781000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-24296000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	36485000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	60781000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-20190000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40591000
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P9Y4M24D
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4100000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3900000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3700000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	4031000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	4006000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	4006000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	4006000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	4006000
CY2023Q4	sclx	Finite Lived Intangible Asset Expected Amortization After Year Five FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFive	16430000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	36485000
CY2023	us-gaap	Debt Instrument Redemption Description DebtInstrumentRedemptionDescription	The Company has the right, but not the obligation, in its sole discretion, to redeem, upon five business days’ prior written notice to Yorkville (the “Redemption Notice”), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.
CY2023Q4	us-gaap	Share Price SharePrice	18
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6854309
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	6899988
CY2023	us-gaap	Payments Of Dividends PaymentsOfDividends	8650000
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	474683
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16939
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.68
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	38942000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	17610
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.02
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	365
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.68
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1060
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.36
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33124
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.38
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7459000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18990
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.78
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y3M18D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	5600000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.24
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	42400000
CY2023	sclx	Weighted Average Period Over Grant WeightedAveragePeriodOverGrant	P3Y1M6D
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	500000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	300000
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	4000000
CY2023Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	0
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	0
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2500000
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2500000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	500000
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1021000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	746000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.111
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.118
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1042000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	916000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	944000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	724000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3626000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	630000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2996000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	759000
CY2023Q4	sclx	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	2237000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	13000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	5000
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	13000
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-16514000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-10396000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-12981000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-11247000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1851000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2472000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-27761000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12247000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15453000
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1471000
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	1347000
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	31000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29232000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10900000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15422000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	71434000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	48984000
CY2023Q4	sclx	Deferred Tax Assets Debt Related Interest DeferredTaxAssetsDebtRelatedInterest	16898000
CY2022Q4	sclx	Deferred Tax Assets Debt Related Interest DeferredTaxAssetsDebtRelatedInterest	15272000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4936000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2014000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3960000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1630000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	525000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1602000
CY2023Q4	sclx	Deferred Tax Assets Accrued Expense And Reserves DeferredTaxAssetsAccruedExpenseAndReserves	1584000
CY2022Q4	sclx	Deferred Tax Assets Accrued Expense And Reserves DeferredTaxAssetsAccruedExpenseAndReserves	568000
CY2023Q4	sclx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	774000
CY2022Q4	sclx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	315000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	159000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	77000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	100270000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	70462000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96776000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	67543000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3494000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2919000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2734000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2666000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	760000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	253000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	3494000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2919000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-24007000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4905000
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19150000
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29232000
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	10900000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	15422000
CY2023	sclx	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	0
CY2022	sclx	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	-9293000
CY2021	sclx	Effective Income Tax Rate Reconciliation Debt Discount Amount EffectiveIncomeTaxRateReconciliationDebtDiscountAmount	8954000
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3798000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	2469000
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	224000
CY2023	sclx	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	260000
CY2022	sclx	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	992000
CY2021	sclx	Income Tax Reconciliation Acquisition Related Charges IncomeTaxReconciliationAcquisitionRelatedCharges	75000
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-5079000
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-713000
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-3968000
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5127000
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-174000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2545000
CY2023	sclx	Effective Income Tax Rate Reconciliation Change In Fair Value Of Convertible Debentures Amount EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount	1752000
CY2022	sclx	Effective Income Tax Rate Reconciliation Change In Fair Value Of Convertible Debentures Amount EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount	0
CY2021	sclx	Effective Income Tax Rate Reconciliation Change In Fair Value Of Convertible Debentures Amount EffectiveIncomeTaxRateReconciliationChangeInFairValueOfConvertibleDebenturesAmount	0
CY2023	sclx	Effective Income Tax Rate Reconciliation Change In Tax Rates Amount EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount	-1471000
CY2022	sclx	Effective Income Tax Rate Reconciliation Change In Tax Rates Amount EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount	0
CY2021	sclx	Effective Income Tax Rate Reconciliation Change In Tax Rates Amount EffectiveIncomeTaxRateReconciliationChangeInTaxRatesAmount	0
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	655000
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	728000
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	993000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	96800000
CY2023Q4	sclx	Indefinite Operating Loss Carryforwards IndefiniteOperatingLossCarryforwards	265900000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	406000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	536000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	2000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	127000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1071000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	408000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	400000
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	400000
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0
CY2023Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-114331000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-23364000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-88424000
CY2023	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	52645000
CY2022	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0
CY2021	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	0
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-166976000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23364000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-88424000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	130298000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	134226000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	132858000
CY2023	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2022	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2021	sclx	Effect Of Dilutive Securities EffectOfDilutiveSecurities	0
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	130298000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	134226000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	132858000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.28
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.28
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	48168217
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27943081
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18967724

Files In Submission

Name	View Source	Status
0000950170-24-029473-index-headers.html	Edgar Link	pending
0000950170-24-029473-index.html	Edgar Link	pending
0000950170-24-029473.txt	Edgar Link	pending
0000950170-24-029473-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img249346191_0.jpg	Edgar Link	pending
img249346191_1.jpg	Edgar Link	pending
img249346191_10.jpg	Edgar Link	pending
img249346191_11.jpg	Edgar Link	pending
img249346191_12.jpg	Edgar Link	pending
img249346191_13.jpg	Edgar Link	pending
img249346191_14.jpg	Edgar Link	pending
img249346191_15.jpg	Edgar Link	pending
img249346191_2.jpg	Edgar Link	pending
img249346191_3.jpg	Edgar Link	pending
img249346191_4.jpg	Edgar Link	pending
img249346191_5.jpg	Edgar Link	pending
img249346191_6.jpg	Edgar Link	pending
img249346191_7.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
img249346191_8.jpg	Edgar Link	pending
img249346191_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sclx-20231231.htm	Edgar Link	pending
sclx-20231231.xsd	Edgar Link	pending
sclx-ex19_1.htm	Edgar Link	pending
sclx-ex23_1.htm	Edgar Link	pending
sclx-ex31_1.htm	Edgar Link	pending
sclx-ex31_2.htm	Edgar Link	pending
sclx-ex32_1.htm	Edgar Link	pending
sclx-ex4_7.htm	Edgar Link	pending
sclx-ex97_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sclx-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCLX
Scilex Holding Co Stock $sclx

2024 Q1 Form 10-K Financial Statement

#000095017024029473 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCLX Scilex Holding Co Stock $sclx

2024 Q1 Form 10-K Financial Statement

#000095017024029473 Filed on March 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCLX
Scilex Holding Co Stock $sclx